Effects of a Prescription Omega-3 Fatty Acid Concentrate on Induced Inflammation

Inflammatory Responses Clinical Trial

— PRONOVA  

Official title:

Effects of a Prescription Omega-3 Fatty Acid Concentrate in a Placebo-controlled Trial of Human Endotoxemia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01813110
• Other study ID #: PRONOVA
• Status: Completed
• Phase: N/A
• Start date: May 2014
• Est. completion date: April 2015

Study information

• Verified date: August 2023
• Source: Penn State University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess whether the marine omega-3 fatty acids can attenuate inflammatory responses to endotoxin challenge.

Description:

Controlled endotoxin infusion has been used widely as a model system to evaluate anti-inflammatory mediators and therapies in a controlled, in vivo setting. It is well established that infusion of bacterial endotoxin (also known as lipopolysaccharide or LPS) in humans results in a marked increase in inflammatory cytokines, most notably TNF-α, IL-1, IL-6 and IL-8, CRP, granulocyte colony stimulating factor (GCSF); eicosanoids, such as prostaglandin (PG) E2 and other mediators. Administration of endotoxin, even at a low dose (0.6 ng/kg) elevates circulating concentrations of inflammatory cytokines, and mimics the inflammatory effects of chronic diseases. This model has been used for decades and has proved to be safe and informative for evaluating anti-inflammatory therapeutic interventions on human inflammation and downstream consequences.

Prolonged or chronic inflammation is involved in the etiology of several diseases such as cardiovascular disease (CVD), diabetes, rheumatoid arthritis, cancer, and neurodegenerative diseases such as Alzheimer's disease. The evidence base clearly demonstrates benefits of diet in ameliorating inflammation and reducing the burden of chronic disease. With respect to marine-derived omega-3 fatty acids and various markers of inflammation related to cardiovascular disease (CVD), both population studies and randomized controlled supplementation trials have yielded mixed results. It is well established that these omega-3 fatty acids are precursors of series-3 prostanoids, thromboxanes, 5-series leukotrienes, and novel lipid mediators such as resolvins and protectins that have anti-inflammatory effects. We hypothesize that supplementation of omega-3 fatty acids will blunt the response to an inflammatory stimulus and/or enhance the resolution phase.

We propose to test this hypothesis using an in vivo endotoxin challenge with a pharmacological dose of omega-3 fatty acid ethyl esters (P-OM3, 3.4 g/d EPA + DHA) in healthy volunteers. Our proposed approach is novel in that we will provoke an in vivo inflammatory response by infusing human subjects with a low dose (0.6 ng/kg body weight) of sterile endotoxin (lipopolysaccharide [LPS]) in contrast to studies that have attempted to reverse established inflammatory pathology. Results from our proposed research will advance our understanding of the effect of omega-3 fatty acids on prevention/attenuation of an inflammatory response.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: April 2015
• Est. primary completion date: April 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 20 Years to 45 Years

Eligibility

Inclusion Criteria:

1. Men between the ages of 20 and 45.

2. BMI =20 and =30

3. Participants who are able to give written informed consent and willing to comply with all study-related procedures.

4. Any race or ethnic background is acceptable

5. Non-smoking

The specific exclusion criteria are:

1. Previous history of vasovagal reactions or unprovoked fainting (I.e. fainting as a result of prolonged standing, exercise)

2. Resting heart rate < 55 bpm

3. History of atherosclerotic cardiovascular disease, including coronary disease, cerebrovascular disease, or peripheral vascular disease

4. History of diabetes mellitus (and/or a fasting glucose >126 mg/dL at screening)

5. Chronic anti-inflammatory medication use or treatment with aspirin, NSAIDs, COX-2 inhibitors; steroids or any immunomodulatory therapy 2 weeks prior to the screening visit

6. Self-reported history of allergy to fish

7. History of a non-skin malignancy within the previous 5 years

8. Renal insufficiency as defined by creatinine outside of lab defined normal range at Screening Visit

9. History of liver disease or abnormal LFTs (AST, ALT, Alk. Phos., GGT > 1.5x ULN; bilirubin > 2x ULN) at Screening Visit

10. Total white blood cell count less than or equal to 3.0 THO/uL

11. Hemoglobin less than 11.0 g/dL

12. Any major active rheumatologic, pulmonary, or dermatologic disease or inflammatory condition or minor active infection

13. Self-reported history of HIV positive

14. Participants who have undergone any organ transplant

15. Individuals who currently use tobacco products or have done so in the previous 30 days.

16. Participants who are unwilling to discontinue use of nutritional supplements, herbs or vitamins unless approved by study staff.

17. Participants who are unwilling to eliminate omega-3 fatty acid (EPA + DHA) supplements and/or fortified food, or have a usual intake of high omega-3 fish (tuna and other non-fried fish) > 2 servings per week

18. Elevated blood pressure (BP > 159/99) or use of any anti-hypertensive medications.

19. Latex allergy

20. Unwillingness to refrain from blood donation for 2 months prior to and following endotoxin administration

21. Any medical condition or abnormal laboratory value that is judged clinically significant by an investigator

22. Inability to take study capsules

23. History of severe, repeated headaches

24. History of migraine

25. Medical condition that causes severe nausea or vomiting

26. Low resting blood pressure (SBP < 90 mmHg)

27. History of atrial fibrillation/flutter

28. Abnormal coagulation parameters (platelet count, prothrombin time with INR), documented coagulation abnormality, or use of anticoagulant medication

29. High LDL-C (> or = 160 mg/dL)

Related Conditions & MeSH terms

• Inflammation
• Inflammatory Responses

Intervention

Drug:
• 4 g prescription omega-3 concentrate
4 g/d prescription omega-3 fatty acid concentrate taken orally for 8-12 weeks
• Placebo
olive oil

Locations

Country	Name	City	State
United States	Penn State University	University Park	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Penn State University	Pronova BioPharma

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in C Reactive Protein (CRP)	Change in blood levels of CRP at 24 hours post endotoxin administration, after each 8 week intervention	24 hours post endotoxin administration, following each 8 week intervention
Secondary	Tumor Necrosis Factor-a (TNF-a)	Change in the plasma concentration of TNF-a at 2 hours post endotoxin administration, after each 8 week intervention	2 hours post endotoxin administration, following each 8 week intervention
Secondary	Interleukin-6 (IL-6)	Change in the plasma concentration of TNF-a at 2 hours post endotoxin administration, after each 8 week intervention	2 hours post endotoxin administration, following each 8 week intervention